Imipramine for vestibular dysfunction in panic disorder: a prospective case series
OBJECTIVE: The purpose of this study was to evaluate the efficacy and effectiveness of imipramine on the treatment of comorbid chronic dizziness and panic disorder. METHOD: Nine patients with panic disorder and agoraphobia associated with chronic dizziness underwent otoneurological screening and wer...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações
2011-04-01
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200011&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849702387842809856 |
|---|---|
| author | Marco Andre Mezzasalma Kátia de Vasconcellos Mathias Isabella Nascimento Alexandre M. Valença Antonio E. Nardi |
| author_facet | Marco Andre Mezzasalma Kátia de Vasconcellos Mathias Isabella Nascimento Alexandre M. Valença Antonio E. Nardi |
| author_sort | Marco Andre Mezzasalma |
| collection | DOAJ |
| description | OBJECTIVE: The purpose of this study was to evaluate the efficacy and effectiveness of imipramine on the treatment of comorbid chronic dizziness and panic disorder. METHOD: Nine patients with panic disorder and agoraphobia associated with chronic dizziness underwent otoneurological screening and were treated with a 3-months course of imipramine. Anxiety levels were measured with the Hamilton Anxiety Scale (HAM-A), dizziness levels were evaluated using the Dizziness Handicap Inventory (DHI), and panic severity and treatment outcome were assessed with the Clinical Global Impression Scale (CGI). RESULTS: At the baseline 33.3% (n=3) had a bilateral peripheral deficit vestibulopathy, the mean scores for HAM-A were 27.2±10.4, for DHI were 51.7±22.7, and for CGI-S were 4.8±0.9. All patients had a significant reduction in their HAM-A (11.1±5.5, p=0.008), DHI (11.5±8.1, p=0.008) and CGI-I (1.8±0.7, p=0.011) levels after 3-months imipramine treatment (mean=72.2±23.2 mg/day). CONCLUSION: This study found a decrease in anxiety levels and in the impact of dizziness in the patients' quality of life after a 3-months treatment course with imipramine. |
| format | Article |
| id | doaj-art-27694cd4e3a742da830938d037713e1e |
| institution | DOAJ |
| issn | 1678-4227 |
| language | English |
| publishDate | 2011-04-01 |
| publisher | Thieme Revinter Publicações |
| record_format | Article |
| series | Arquivos de Neuro-Psiquiatria |
| spelling | doaj-art-27694cd4e3a742da830938d037713e1e2025-08-20T03:17:40ZengThieme Revinter PublicaçõesArquivos de Neuro-Psiquiatria1678-42272011-04-01692a19620110.1590/S0004-282X2011000200011S0004-282X2011000200011Imipramine for vestibular dysfunction in panic disorder: a prospective case seriesMarco Andre Mezzasalma0Kátia de Vasconcellos Mathias1Isabella Nascimento2Alexandre M. Valença3Antonio E. Nardi4Universidade Federal do Rio de JaneiroUniversidade Federal do Rio de JaneiroUniversidade Federal do Rio de JaneiroUniversidade Federal FluminenseUniversidade Federal do Rio de JaneiroOBJECTIVE: The purpose of this study was to evaluate the efficacy and effectiveness of imipramine on the treatment of comorbid chronic dizziness and panic disorder. METHOD: Nine patients with panic disorder and agoraphobia associated with chronic dizziness underwent otoneurological screening and were treated with a 3-months course of imipramine. Anxiety levels were measured with the Hamilton Anxiety Scale (HAM-A), dizziness levels were evaluated using the Dizziness Handicap Inventory (DHI), and panic severity and treatment outcome were assessed with the Clinical Global Impression Scale (CGI). RESULTS: At the baseline 33.3% (n=3) had a bilateral peripheral deficit vestibulopathy, the mean scores for HAM-A were 27.2±10.4, for DHI were 51.7±22.7, and for CGI-S were 4.8±0.9. All patients had a significant reduction in their HAM-A (11.1±5.5, p=0.008), DHI (11.5±8.1, p=0.008) and CGI-I (1.8±0.7, p=0.011) levels after 3-months imipramine treatment (mean=72.2±23.2 mg/day). CONCLUSION: This study found a decrease in anxiety levels and in the impact of dizziness in the patients' quality of life after a 3-months treatment course with imipramine.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200011&lng=en&tlng=entonturatranstorno de pânicoimipraminatranstornos de ansiedade |
| spellingShingle | Marco Andre Mezzasalma Kátia de Vasconcellos Mathias Isabella Nascimento Alexandre M. Valença Antonio E. Nardi Imipramine for vestibular dysfunction in panic disorder: a prospective case series Arquivos de Neuro-Psiquiatria tontura transtorno de pânico imipramina transtornos de ansiedade |
| title | Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
| title_full | Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
| title_fullStr | Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
| title_full_unstemmed | Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
| title_short | Imipramine for vestibular dysfunction in panic disorder: a prospective case series |
| title_sort | imipramine for vestibular dysfunction in panic disorder a prospective case series |
| topic | tontura transtorno de pânico imipramina transtornos de ansiedade |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2011000200011&lng=en&tlng=en |
| work_keys_str_mv | AT marcoandremezzasalma imipramineforvestibulardysfunctioninpanicdisorderaprospectivecaseseries AT katiadevasconcellosmathias imipramineforvestibulardysfunctioninpanicdisorderaprospectivecaseseries AT isabellanascimento imipramineforvestibulardysfunctioninpanicdisorderaprospectivecaseseries AT alexandremvalenca imipramineforvestibulardysfunctioninpanicdisorderaprospectivecaseseries AT antonioenardi imipramineforvestibulardysfunctioninpanicdisorderaprospectivecaseseries |